Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 19/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709394 | 0.83 | MTOR (0.74) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3717941 | 0.80 | MTOR (1.00) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3704872 | 0.79 | MTOR (0.72) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3781410 | 0.78 | MTOR (0.86) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3706365 | 0.78 | MTOR (0.67) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3710315 | 0.78 | MTOR (0.67) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3788806 | 0.78 | MTOR (1.00) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3705124 | 0.77 | MTOR (0.75) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL9948507 | 0.77 | MTOR (1.00) | MTORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3786606 | 0.77 | MTOR (0.79) | MTORPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | claimed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | MTOR 1/4885PIK3CD 8/4885PIK3CA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.